Buprenorphine and naloxone sublingual tablets for opioid dependence maintenance

Buprenorphine and naloxone sublingual tablets combine a partial opioid agonist with an opioid antagonist to treat opioid dependence. They are intended for daily sublingual administration as part of a comprehensive treatment program that also includes counseling and psychosocial support.

These tablets are prescribed for the maintenance treatment of opioid dependence in patients who have already undergone induction with buprenorphine sublingual tablets. Treatment is part of a broader plan incorporating psychosocial interventions to support recovery.

Buprenorphine hydrochloride; Naloxone hydrochloride dihydrate

Buprenorphine, a partial opioid agonist, activates opioid receptors but with less intensity than full agonists, helping to reduce withdrawal symptoms and cravings. Naloxone is an opioid antagonist included to deter misuse by injection, as it can precipitate withdrawal if administered parenterally.

Buprenorphine and naloxone tablets are given once daily by placing the tablet(s) under the tongue until fully dissolved; tablets must be administered whole without cutting, chewing, or swallowing.

• Dosing is adjusted incrementally (2 mg/0.5 mg or 4 mg/1 mg of buprenorphine/naloxone) to suppress opioid withdrawal symptoms while maintaining treatment.
• The usual maintenance dose ranges from 4 mg/1 mg to 24 mg/6 mg daily; doses above 24 mg/6 mg have not been studied in clinical trials but may be used in some patients.
• After induction with buprenorphine sublingual tablets, patients are switched to these combined tablets for ongoing maintenance.
• Patients may be treated indefinitely as long as benefits persist and treatment goals are met.
• Supervised dosing is recommended initially, progressing to unsupervised use as clinical stability allows.
• Treatment discontinuation should be done by gradual tapering to minimize withdrawal symptoms.
• When switching between film and tablet formulations, initiate with the same dose but monitor for over- or under-dosing due to possible bioavailability differences.

Patients should avoid eating or drinking until tablets dissolve fully, and wait at least one hour before brushing teeth after dosing.

Confirmed hypersensitivity to buprenorphine or naloxone is a contraindication due to risk of serious allergic reactions including anaphylaxis.

Serious risks include:

• Addiction, abuse, and misuse: Buprenorphine has abuse potential similar to other opioids. Monitor closely and avoid multiple refills early in treatment or without proper follow-up.
• Respiratory depression: Life-threatening respiratory depression and death have occurred, especially when combined with benzodiazepines or other CNS depressants. Warn patients of these dangers.
• Unintentional pediatric exposure: Store tablets securely to prevent accidental ingestion leading to severe or fatal respiratory depression in children.
• Neonatal opioid withdrawal syndrome: Risk in newborns after prolonged opioid exposure during pregnancy.
• Adrenal insufficiency: May occur; treat with corticosteroids and taper opioid use if diagnosed.
• Risk of withdrawal with abrupt discontinuation: Monitor for withdrawal symptoms and treat accordingly if therapy is interrupted.
• Hepatic events: Monitor liver function before and during treatment; evaluate if hepatic issues arise.
• Precipitation of opioid withdrawal: Can occur if administered before opioid agonist effects have subsided, especially with parenteral misuse.
• Overdose risk in opioid-naïve individuals: Not indicated for analgesia; deaths have been reported in opioid-naïve patients taking 2 mg doses.

Patients should be educated on the signs of respiratory depression and the importance of emergency response if overdose suspected.

Strongly consider prescribing or recommending naloxone or other opioid overdose reversal agents both at treatment initiation and renewal, especially for patients or household members at risk.

Concomitant use of benzodiazepines or other central nervous system depressants increases the risk of respiratory depression. Avoid or use caution with these agents during treatment.

Overdose may cause life-threatening respiratory depression. In case of buprenorphine overdose, higher or repeated doses of opioid overdose reversal agents like naloxone may be needed due to buprenorphine’s long duration and strong receptor affinity.